U.S. Markets closed

Misonix Fiscal 2019 Second Quarter Revenue Rises 22% to a Record $10.2 Million

FARMINGDALE, N.Y., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today reported financial results for the fiscal 2019 second quarter ended December 31, 2018 as summarized below:

  Three Months Ended   Six Months Ended
  December 31,   December 31,
    2018     2017       2018     2017  
           
Revenue $ 10,176,453   $ 8,323,845     $ 19,537,617   $ 15,604,568  
Gross Profit $ 7,128,374   $ 5,858,019     $ 13,738,995   $ 10,961,387  
GP Percentage - product revenue   70.0%     70.4%       70.3%     70.2%  
Pretax loss $ (840,333 ) $ (1,332,352 )   $ (3,451,317 ) $ (2,825,576 )
Net loss $ (840,333 ) $ (6,856,774 )   $ (3,451,317 ) $ (8,068,998 )
           
EBITDA (1) $ (439,786 ) $ (1,021,648 )   $ (2,684,182 ) $ (2,148,284 )
Adjusted EBITDA (1) $ 380,909   $ 421,578     $ (195,682 ) $ 424,035  
           
  December 31, June 30,      
    2018     2018        
Long Term Debt $ -   $ -        
Cash and cash equivalents $ 10,173,286   $ 10,979,455        

  
(1) Definitions and disclosures regarding non-GAAP financial information including reconciliations are included on page 6 of this press release.

Stavros Vizirgianakis, President and Chief Executive Officer of Misonix stated, “Misonix’s financial growth momentum continued in the fiscal second quarter, reflecting the ongoing successful execution of our go-to-market strategies, including our direct sales team, which has expanded our domestic market share. Growing demand for our leading ultrasonic surgical products resulted in a 22% year-over-year rise in total fiscal second quarter revenues to a record $10.2 million, including a 23% increase in consumables revenue and a 21% gain in equipment revenue. Our ability to generate revenue growth, while maintaining a healthy gross margin of approximately 70%, is highlighted by the 22% year-over-year increase in second quarter gross profit to a record $7.1 million. We were able to maintain Misonix’s double-digit top-line growth trajectory, generating 25% year-over-year growth in total revenues through the first six months of fiscal 2019. Importantly, our financial results for the second quarter and first half of fiscal 2019 confirm the benefits of our recent investments and accelerating demand for the demonstrated clinical benefits that our ultrasonic medical devices deliver to physicians, hospitals and patients.

“During the second quarter, we further developed our direct commercialization team while training our international distribution partners. These initiatives will enable Misonix to further penetrate existing and new markets as we prepare for the launch of Nexus, our new ultrasonic surgical platform, which we intend to launch in the second half of fiscal 2019. In addition, we are already realizing value from the recent systems and infrastructure enhancements made to support our continued growth and expect these investments to drive additional operating efficiencies across the business in the coming quarters.

“Since unveiling Nexus at the 2018 NASS Conference, we have received overwhelmingly positive feedback from surgeons and the overall market, which provides us with added confidence for its potential to serve as a third growth engine for the Company as we benefit from cross-selling opportunities, especially through deeper penetration of current customer accounts and the expansion of our addressable markets to a broader range of procedures beyond those served by our current products. While medical professionals are the driving force behind successful outcomes, Nexus presents surgeons with a powerful tool to remove hard and soft tissue with greater control, accuracy and efficiency. By incorporating multiple modalities into one modern platform with extensive functionalities, we believe Nexus will be a requisite addition to the operating room as it delivers demonstrated clinical benefits at a compelling value proposition for hospitals and outpatient clinics.
           
“Looking ahead, we are excited about the opportunities to enhance shareholder value as we continue pursuing the Company’s next phase of growth. As we bring the next generation of ultrasonic products to market and complete our transformation to a direct commercialization platform, we remain confident in our ability to generate double-digit top-line growth and improved profitability in the second half of fiscal 2019.”

Sales Performance Supplemental Data

    For the three months ended        
    December 31,   Net change
      2018     2017   $   %
Total                
Consumables   $ 7,570,395   $ 6,162,064   $ 1,408,331     22.9 %
Equipment     2,606,058     2,161,781     444,277     20.6 %
Total   $ 10,176,453   $ 8,323,845   $ 1,852,608     22.3 %
                 
Domestic:                
Consumables   $ 5,477,995   $ 4,623,545   $ 854,450     18.5 %
Equipment     600,559     776,878     (176,319 )   -22.7 %
Total   $ 6,078,554   $ 5,400,423   $ 678,131     12.6 %
                 
International:                
Consumables   $ 2,092,400   $ 1,538,519   $ 553,881     36.0 %
Equipment     2,005,499     1,384,903     620,596     44.8 %
Total   $ 4,097,899   $ 2,923,422   $ 1,174,477     40.2 %

Joe Dwyer, Chief Financial Officer, added, “Our fiscal 2019 second quarter results marked another outstanding quarter for Misonix, resulting in continued robust top-line growth, healthy margins and an improved bottom line, highlighting our successful execution across multiple fronts.

“During the first half of fiscal 2019, we undertook a range of initiatives to eliminate inefficiencies in our procurement and distribution, including bringing new suppliers on board and diversifying our supply chain. We also fully transitioned to a significantly more capable ERP system as well as instituted new policies to ensure optimal inventory levels and fulfillment outcomes. With these initiatives now largely behind us, we are confident in our ability to successfully and efficiently meet the added demand we expect.

“As we enter the second half of fiscal 2019, we remain well-positioned to continue to invest in our products and further improve our operations and our position in the market. We are confident that we have the capital flexibility we need, including $10.2 million in cash and no debt, to ensure that we adequately support our growth via both organic and inorganic growth initiatives and look forward to driving long-term value for our shareholders as we remain disciplined and focused in generating attractive rates of returns. Looking ahead to the second half of fiscal 2019, we reiterate our guidance for product revenue growth in excess of 20% for fiscal 2019, along with gross profit margins of approximately 70%.”

Fiscal Second Quarter 2019 Conference Call 
Misonix will host a conference call and webcast today, Wednesday, February 6, 2019, at 4:30 p.m. ET to discuss its financial results and operations and host a question and answer session. The dial in number for the audio conference call is 888-599-8686 (domestic) or 323-994-2093 (international), conference ID 9194323. Participants may also listen to a live webcast of the call at the Company’s website through the “Events and Presentations” section under “Investor Relations” at www.misonix.com.  Following its completion, a replay of the webcast will be available for 30 days on the Company’s website, www.misonix.com.

About Misonix, Inc. 
Misonix, Inc. (MSON) designs, manufactures and markets ultrasonic medical devices for the precise removal of hard and soft tissue, including bone removal, wound debridement and ultrasonic aspiration. Misonix is focused on leveraging its proprietary ultrasonic technology to become the standard of care in operating rooms and clinics around the world. Misonix's proprietary ultrasonic medical devices are used in a growing number of medical procedures, including spine surgery, neurosurgery, orthopedic surgery, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. At Misonix, Better Matters to us. That is why throughout the Company’s history, Misonix has maintained its commitment to medical technology innovation and the development of ultrasonic surgical products that radically improve patient outcomes. Additional information is available on the Company's web site at www.misonix.com.

Safe Harbor Statement 
With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, the impact of the pending investigation by the Department of Justice and Securities Exchange Commission, and other factors discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2018, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking statements.

Contact:   
Joe Dwyer
Chief Financial Officer
Misonix, Inc.
631-694-9555

Joseph Jaffoni, Norberto Aja, Jennifer Neuman
JCIR 
212-835-8500 or mson@jcir.com


MISONIX INC. and Subsidiaries    
Consolidated Statements of Operations    
(Unaudited)  
   
    For the three months ended     For the six months ended  
    December 31,     December 31,  
    2018   2017     2018   2017  
                     
Revenues                    
  Product    $  10,176,453    $  8,323,845      $  19,537,617    $  15,604,568  
Total revenue     10,176,453     8,323,845       19,537,617     15,604,568  
                     
Cost of goods sold     3,048,079     2,465,826       5,798,622     4,643,181  
Gross profit     7,128,374     5,858,019       13,738,995     10,961,387  
Operating expenses:                    
Selling expenses     4,800,643     3,919,515       9,535,648     7,490,228  
General and administrative expenses     2,347,184     2,380,860       5,530,568     4,953,991  
Research and development expenses     839,219     957,204       2,143,984     1,858,478  
Total operating expenses     7,987,046     7,257,579       17,210,200     14,302,697  
Loss from operations     (858,672 )   (1,399,560 )     (3,471,205 )   (3,341,310 )
                     
Other income (expense):                    
Interest income     17,242     45       37,056     58  
Royalty income     1,105     71,550       1,105     524,521  
Other     (8 )   (4,387 )     (18,273 )   (8,845 )
Total other income     18,339     67,208       19,888     515,734  
                     
Loss from operations before income taxes     (840,333 )   (1,332,352 )     (3,451,317 )   (2,825,576 )
                     
Income tax expense     -     5,524,422       -     5,243,422  
Net loss    $  (840,333 )  $  (6,856,774 )    $  (3,451,317 )  $  (8,068,998 )
                     
Net loss per share:                    
Basic    $  (0.09 )  $  (0.76 )    $  (0.37 )  $  (0.90 )
Diluted    $  (0.09 )  $  (0.76 )    $  (0.37 )  $  (0.90 )
                     
Weighted average shares - Basic     9,322,237     8,977,984       9,210,031     8,968,195  
Weighted average shares - Diluted     9,322,237     8,977,984       9,210,031     8,968,195  
                     


Misonix, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
         
    December 31,   June 30,
      2018       2018  
    (Unaudited)    
Assets        
Current assets:        
Cash and cash equivalents   $ 10,173,286     $ 10,979,455  
Accounts receivable, less allowance for doubtful accounts of $250,000 and $200,000, respectively     5,709,298       5,245,549  
Inventories, net     5,711,528       5,019,886  
Prepaid expenses and other current assets     601,752       611,647  
Total current assets     22,195,864       21,856,537  
         
Property, plant and equipment, net of accumulated amortization and depreciation of $9,720,862 and $9,023,235, respectively     4,473,859       4,188,378  
Patents, net of accumulated amortization of $1,132,901 and $1,063,393, respectively     763,044       757,447  
Goodwill     1,701,094       1,701,094  
Contract assets     960,000       -  
Intangible and other assets     451,315       517,295  
Total assets   $ 30,545,176     $ 29,020,751  
         
Liabilities and shareholders' equity        
Current liabilities:        
Accounts payable   $ 3,592,287     $ 1,794,098  
Accrued expenses and other current liabilities     2,264,112       2,411,172  
Deferred income     5,993       13,303  
Total current liabilities     5,862,392       4,218,573  
         
Non current liabilities     401,000       401,000  
Total liabilities   $ 6,263,392     $ 4,619,573  
         
Commitments and contingencies        
         
Shareholders' equity:        
Common stock, $.01 par value-shares authorized 40,000,000; 9,584,178 and 9,430,466 shares issued and outstanding in each period     95,842       94,305  
Additional paid-in capital     42,143,359       39,772,973  
Accumulated deficit     (17,957,417 )     (15,466,100 )
Total shareholders' equity     24,281,784       24,401,178  
         
Total liabilities and shareholders' equity   $ 30,545,176     $ 29,020,751  
         

Use of Non-GAAP Financial Measures

The Company has presented the following non-GAAP financial measures in this press release: EBITDA and Adjusted EBITDA. The Company defines EBITDA as the net income (loss) as reported under GAAP, plus depreciation and amortization expense, interest expense and income tax expense (benefit). The Company defines Adjusted EBITDA as EBITDA plus non-cash stock compensation expense and engineering costs associated with its development of Nexus, its next generation platform, which will not be a recurring cost when the project is completed in the second half of fiscal 2019.

We present these non-GAAP measures because we believe these measures are useful indicators of our operating performance. Our management uses these non-GAAP measures principally as a measure of our operating performance and believes that these measures are useful to investors because they are frequently used by analysts, investors and other interested parties to evaluate the operating performance of companies in our industry. We also believe that these measures are useful to our management and investors as a measure of comparative operating performance from period to period.

           
  Three Months Ended     Six Months Ended  
  December 31,     December 31,  
  2018   2017     2018   2017  
                   
EBITDA:                  
Net loss  $  (840,333 )  $  (6,856,774 )    $  (3,451,317 )  $  (8,068,998 )
Depreciation and amortization   400,547     310,704       767,135     677,292  
Income tax benefits   -      5,524,422       -      5,243,422  
EBITDA   (439,786 )   (1,021,648 )     (2,684,182 )   (2,148,284 )
                   
Non-cash stock compensation   500,088     844,601       1,504,586     1,469,894  
Nexus next generation engineering   320,607     598,625       983,914     1,102,425  
Adjusted EBITDA  $  380,909    $  421,578      $  (195,682 )  $  424,035